tiprankstipranks
Trending News
More News >

CStone Pharmaceuticals Secures NMPA Approval for Local Manufacturing of GAVRETO® in China

Story Highlights
CStone Pharmaceuticals Secures NMPA Approval for Local Manufacturing of GAVRETO® in China

Don’t Miss TipRanks’ Half-Year Sale

An announcement from CStone Pharmaceuticals ( (HK:2616) ) is now available.

CStone Pharmaceuticals announced that the National Medical Products Administration of China has approved the localized manufacturing of GAVRETO® (pralsetinib) for the Chinese market, starting in 2026. This transition from imported to locally manufactured products is expected to enhance supply chain flexibility and resilience, ensuring sustainable product access and strengthening GAVRETO®’s market position. The approval marks a significant milestone in CStone’s lifecycle management strategy, aiming to improve treatment accessibility for RET-positive patients in China.

More about CStone Pharmaceuticals

CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focusing on the research and development of anti-cancer therapies. The company has launched four innovative drugs and secured approvals for 16 new drug applications covering nine indications. CStone’s pipeline includes promising candidates such as antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines. The company is committed to addressing unmet medical needs in China and globally, supported by a management team with extensive experience across the drug development spectrum.

Average Trading Volume: 12,612,220

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.94B

For detailed information about 2616 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1